Despite the fact that antigens such as CD19 and B-cell maturation antigen (BCMA) have been successfully targeted by CARs in the setting of hematopoietic cancer, there is an unmet need to identify similarly ideal antigens expressed by solid tumors. This evidence concerns the gene TNFRSF17 and hematopoietic and lymphoid cell neoplasm.